CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) ...

Sacramento-based UC Davis Comprehensive Cancer Center will use next generation sequencing analysis on patients diagnosed with hematological malignancies and pancreatic cancer. The strategy will be ...

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...

Chicago artificial intelligence giant Tempus AI is showing it's operating in the black after 10 years and growing.

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...